ID Name Structure References (top 5) Molecular Target(s)


in 4 ingredients:

  • 9
  • 51
  • 429
  • 459

  • Properties
    C29H39NO9    545.63

    1:  Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y.
    In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
    Blood.    impact factor:   8.782
    2001;  97(7): 1999-2007

    2:  O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M.
    Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
    Blood.    impact factor:   8.782
    1999;  93(12): 4149-53

    3:  Kantarjian HM, O'Brien S, Anderlini P, Talpaz M.
    Treatment of myelogenous leukemia: current status and investigational options.
    Blood.    impact factor:   8.782
    1996;  87(8): 3069-81

    4:  O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M.
    Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
    Blood.    impact factor:   8.782
    1995;  86(9): 3322-6

    5:  Zhou JY, Chen DL, Shen ZS, Koeffler HP.
    Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro.
    Cancer Res.    impact factor:   8.614
    1990;  50(7): 2031-5

    Time used: 125 milliseconds.

    Webpage designed by Dr. Xueliang Fang, last updated on 3/10/2005